Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field

Insights into advanced therapies in the context of evolving funding and M&A environments

Fit for function: developing potency assays reflective of the in vivo environment

Gene therapy is having a monumental year: how can the industry keep up with supply?

A deep dive in to generative AI applications in I-O

Developing novel radioimmunotherapy combinations for lung cancer treatment

Focusing on the fundamentals: what do and don’t we know about mRNA delivery?

Navigating genomics and transcriptomics in the immuno-oncology space

Avian influenza and the risk of pandemic

Exploring the landscape of novel targets & pathways in immuno-oncology

Multiomics integration: advancing pediatric cancer immunotherapy

Building with the patient in mind: designing a state-of-the-art facility for viral vector manufacturing

Can AAV continue to deliver the promise of gene therapy?

Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)

Investing long-term in the cell & gene therapies of the future

Happy medium: considerations in scaling cell culture media strategies

Applying multiomics to novel target discovery in immuno-oncology

Modernizing cell therapy manufacturing to reduce vein-to-vein times

Inducing innate immune responses with particulate adjuvants

Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development